UK-Backed PharosAI Cancer Data Project Using Xenium Might Change The Case For Investing In 10x Genomics (TXG)

On 4 February 2026, PharosAI announced it would use 10x Genomics’ Xenium spatial platform to convert archived NHS cancer ...
Nasdaq

10x Genomics Launches Xenium Protein, Advancing Spatial Biology by Enabling Same-Cell RNA and Protein Analysis

First fully integrated spatial multiomic assay from 10x Genomics brings RNA and protein data together in situ – unlocking deeper insights into cell function and disease biology "Scientists can now ...

PharosAI and 10x Genomics Partner to Transform Cancer Research with AI and Spatial Biology

Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that PharosAI, a research ...
Seeking Alpha

High Sensitivity and Specificity of the Xenium Platform from 10x Genomics Outperforms NanoString's CosMx and Vizgen's Merscope in Benchmarking Preprint

Xenium In Situ demonstrates higher transcript counts per gene in new comparison study of three spatial imaging platforms PLEASANTON, Calif., Dec. 13, 2023 /PRNewswire/ -- 10x Genomics, Inc. (TXG) ...

10x Genomics PharosAI Cancer Project Tests Xenium’s Long Term Investment Case

Genomics is collaborating with PharosAI and leading UK institutions to build a large multimodal cancer dataset using its Xenium spatial platform. The project will use decades of NHS cancer samples to ...
The Manila Times

Omics Empower Hong Kong Launches Xenium™ In Situ Spatial Transcriptomics Services

Omics Empower, a global life science service provider specializing in single-cell sequencing and spatial transcriptomics, announced that Xenium™ In Situ Spatial Transcriptomics services are now ...